| Literature DB >> 34021240 |
Fiona C Simpson1,2,3,4, Christopher D McTiernan5, Mohammad Mirazul Islam6, Oleksiy Buznyk7,8, Philip N Lewis9, Keith M Meek9, Michel Haagdorens10, Cindy Audiger1,11, Sylvie Lesage1,11, François-Xavier Gueriot1,12, Isabelle Brunette1,2, Marie-Claude Robert1,4, David Olsen13, Laura Koivusalo14, Aneta Liszka7, Per Fagerholm15, Miguel Gonzalez-Andrades16,17, May Griffith18,19,20,21.
Abstract
The long-term survival of biomaterial implants is often hampered by surgery-induced inflammation that can lead to graft failure. Considering that most corneas receiving grafts are either pathological or inflamed before implantation, the risk of rejection is heightened. Here, we show that bioengineered, fully synthetic, and robust corneal implants can be manufactured from a collagen analog (collagen-like peptide-polyethylene glycol hybrid, CLP-PEG) and inflammation-suppressing polymeric 2-methacryloyloxyethyl phosphorylcholine (MPC) when stabilized with the triazine-based crosslinker 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride. The resulting CLP-PEG-MPC implants led to reduced corneal swelling, haze, and neovascularization in comparison to CLP-PEG only implants when grafted into a mini-pig cornea alkali burn model of inflammation over 12 months. Implants incorporating MPC allowed for faster nerve regeneration and recovery of corneal sensation. CLP-PEG-MPC implants appear to be at a more advanced stage of regeneration than the CLP-PEG only implants, as evidenced by the presence of higher amounts of cornea-specific type V collagen, and a corresponding decrease in the presence of extracellular vesicles and exosomes in the corneal stroma, in keeping with the amounts present in healthy, unoperated corneas.Entities:
Year: 2021 PMID: 34021240 DOI: 10.1038/s42003-021-02108-y
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642